-+ 0.00%
-+ 0.00%
-+ 0.00%

XORTX Therapeutics’ three-month net loss ended Sept. 30 narrows 41% to USD 382,100

PUBT·11/16/2026 11:13:59
Listen to the news
XORTX Therapeutics’ three-month net loss ended Sept. 30 narrows 41% to USD 382,100
  • XORTX Therapeutics’ net loss narrowed 41% year-over-year to USD 382,100 for the three months ended September 30, 2026.
  • Operating cash outflow more than doubled year-over-year to USD 4.34 million for the nine months ended September 30, 2026.
  • Cash fell 63% from December 31, 2025, to USD 318,846 at September 30, 2026.
  • The acquisition of Vectus Biosystems’ VB4-P5 renal anti-fibrotic therapeutic program closed April 13, 2026, with a total cost of USD 2.34 million.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. XORTX Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-26-007439), on November 16, 2026, and is solely responsible for the information contained therein.